Document is current
Any future updates will be listed below
-
Authors
Yao, Song https://orcid.org/0000-0001-9442-1313
Campbell, Peter T.
Ugai, Tomotaka
Gierach, Gretchen
Abubakar, Mustapha
Adalsteinsson, Viktor
Almeida, Jonas
Brennan, Paul
Chanock, Stephen
Golub, Todd
Hanash, Samir
Harris, Curtis
Hathaway, Cassandra A.
Kelsey, Karl
Landi, Maria Teresa
Mahmood, Faisal
Newton, Christina
Quackenbush, John
Rodig, Scott
Schultz, Nikolaus
Tearney, Guillermo
Tworoger, Shelley S.
Wang, Molin
Zhang, Xuehong
Garcia-Closas, Montserrat
Rebbeck, Timothy R.
Ambrosone, Christine B.
Ogino, Shuji
-
Funding
Funding for this research was provided by:
Division of Cancer Epidemiology and Genetics, National Cancer Institute (R35 CA197735)
- License Information
-
More Information
Article History
Received: 15 October 2021
Accepted: 20 May 2022
First Online: 27 June 2022
Declarations
:
: Dr. Scott Rodig receives research support from Bristol-Myers Squibb, Merck, KITE/Gilead, and Affimed. Dr. Rodig is on the SAB for Immunitas Therapeutics and has stock options in the company. Dr. Guillermo Tearney received sponsored research funding from Xsphera Biosciences. Dr. Karl Kelsey is a founder of Cellintec which had no role in this research. No other authors declare conflicts of interest related to the work presented here.
